Abstract
Hypertrophic cardiomyopathy (HCM) is microscopically characterized by cardiomyocyte hypertrophy, myofibrillar disarray, and fibrosis. During the evolvement of the hypertrophic disease, myocardium suffers a heterogeneous remodeling which includes enhancement of extracellular matrix. The most commonly used pharmacological agents are β- blockers and verapamil, a calcium antagonist, which are the mainstay of therapy. Their proposed mechanisms of effect include improved ventricular relaxation, and increased diastolic filling time but its impact on HCM pathophysiology remains unclear. The results of genetic and pharmacological studies in animal models suggest that cardiac hypertrophy and fibrosis in HCM are potentially reversible. However, current pharmacological treatments of HCM in patients, while are effective for symptomatic improvement, have not been established to prevent, ameliorate, or reverse cardiac hypertrophy in patients. An effective treatment of HCM has to target the molecular mechanisms that are involved in the pathogenesis of the phenotype and novel pharmacological therapies are moving in that direction. In this review, we analyse potential beneficial effects of specific experimental pharmacological agents on decreasing myocardial hypertrophy, regression of fibrosis or improving myocardial metabolic efficiency.
Keywords: Hypertrophic cardiomyopathy, fibrosis, losartan, spironolactone, statins, calcineurin inhibitors, perhexiline, Nacetylcysteine, HCM, HMG-CoA, NF-AT3, CsA, TGF
Medicinal Chemistry
Title: An Insight of Novel Pharmacological Therapies in Hypertrophic Cardiomyopathy
Volume: 7 Issue: 4
Author(s): Esteban Orenes-Pinero, Diana Hernandez-Romero, Eva Jover, Gonzalo de la Morena, Mariano Valdes and Francisco Marin
Affiliation:
Keywords: Hypertrophic cardiomyopathy, fibrosis, losartan, spironolactone, statins, calcineurin inhibitors, perhexiline, Nacetylcysteine, HCM, HMG-CoA, NF-AT3, CsA, TGF
Abstract: Hypertrophic cardiomyopathy (HCM) is microscopically characterized by cardiomyocyte hypertrophy, myofibrillar disarray, and fibrosis. During the evolvement of the hypertrophic disease, myocardium suffers a heterogeneous remodeling which includes enhancement of extracellular matrix. The most commonly used pharmacological agents are β- blockers and verapamil, a calcium antagonist, which are the mainstay of therapy. Their proposed mechanisms of effect include improved ventricular relaxation, and increased diastolic filling time but its impact on HCM pathophysiology remains unclear. The results of genetic and pharmacological studies in animal models suggest that cardiac hypertrophy and fibrosis in HCM are potentially reversible. However, current pharmacological treatments of HCM in patients, while are effective for symptomatic improvement, have not been established to prevent, ameliorate, or reverse cardiac hypertrophy in patients. An effective treatment of HCM has to target the molecular mechanisms that are involved in the pathogenesis of the phenotype and novel pharmacological therapies are moving in that direction. In this review, we analyse potential beneficial effects of specific experimental pharmacological agents on decreasing myocardial hypertrophy, regression of fibrosis or improving myocardial metabolic efficiency.
Export Options
About this article
Cite this article as:
Orenes-Pinero Esteban, Hernandez-Romero Diana, Jover Eva, de la Morena Gonzalo, Valdes Mariano and Marin Francisco, An Insight of Novel Pharmacological Therapies in Hypertrophic Cardiomyopathy, Medicinal Chemistry 2011; 7 (4) . https://dx.doi.org/10.2174/157340611796150941
DOI https://dx.doi.org/10.2174/157340611796150941 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
Call for Papers in Thematic Issues
Carbohydrates in Computational and Medicinal Chemistry
Carbohydrates are the most essential organic molecules and are involved in the maintenance of various physiological and metabolic processes in living organisms. Carbohydrate-based compounds have come to the attention of researchers because of their significant contributions to biological functions, such as cell development and cell proliferation, connections between several cells, ...read more
Recent Advances in the Medicinal Chemistry of Cancer
Scope of the Thematic Issue: Correlation between structure and function is one of the important aspects of the success of anti-cancer compounds associated with their structure-activity interactions, physiology, biochemical, molecular, and genetic processes. Overcoming these obstacles is key to obtaining further insights into developments in rational drug design, bioorganic chemistry, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Echocardiographic Hemodynamic Monitoring in the Critically Ill Patient
Current Cardiology Reviews Molecular Replacement in Cancer Therapy: Reversing Cancer Metabolic and Mitochondrial Dysfunction, Fatigue and the Adverse Effects of Cancer Therapy
Current Cancer Therapy Reviews Fibrosis as a Therapeutic Target Post-Myocardial Infarction
Current Pharmaceutical Design Cardiac Amyloid - A Hidden Contributor to Cardiac Dysfunction Following Cardiac Surgery: Case Report and Literature Review
Current Cardiology Reviews Murine Models of Vpr-Mediated Pathogenesis
Current HIV Research Successful Radiofrequency Ablation of Atrial Flutter Causing Hemodynamic Instability in a Patient with Recent Myocardial Infarction
Current Cardiology Reviews Postoperative Atrial Fibrillation - What Do We Really Know?
Current Vascular Pharmacology The Cardiovascular Nutrapharmacology of Resveratrol: Pharmacokinetics, Molecular Mechanisms and Therapeutic Potential
Current Medicinal Chemistry Beta-Blockers: Current State of Knowledge and Perspectives
Mini-Reviews in Medicinal Chemistry Chagas Disease: Progress and New Perspectives
Current Medicinal Chemistry Caveolin-3: Its Importance in Muscle Function and Pathology
Current Genomics Cocaine Dependence and Stroke: Pathogenesis and Management
Current Neurovascular Research Hemolytic Uremic Syndrome in Children
Current Pediatric Reviews Pleiotropic Effects of Fenofibrate
Current Pharmaceutical Design Potential Treatment of Cardiac Hypertrophy and Heart Failure by Inhibiting the Sarcolemmal Binding of Phospholipase Cβ1b
Current Drug Targets Intracellular Calcium Homeostasis and Kidney Disease
Current Medicinal Chemistry Systemic Redox Biomarkers in Neurodegenerative Diseases
Current Drug Metabolism The Anti-fibrotic Hormone Relaxin is not Reno-protective, Despite Being Active, in an Experimental Model of Type 1 Diabetes
Protein & Peptide Letters High Sensitivity Troponin in Cardiovascular Disease. Is There More Than a Marker of Myocardial Death?
Current Topics in Medicinal Chemistry In vitro Generated Mesenchymal Stem Cells: Suitable Tools to Target Insulin Dependent Diabetes Mellitus?
Current Stem Cell Research & Therapy